Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions

Abstract

Spanish

French

OBJECTIVE:

To review the pharmacokinetics and pharmacodynamics of oral and intravenous azithromycin compared with other macrolide antibiotics, and to evaluate these differences and their relation to clinical effectiveness.

DATA SOURCE:

A MEDLINE search (1966–May 1998) was performed to identify applicable English-language clinical, animal, and microbiologic studies pertaining to pharmacokinetic and pharmacodynamic parameters.

STUDY SELECTION:

Relevant studies concerning microbiology, pharmacokinetics, tissue concentrations, pharmacodynamics, and the clinical effects of these parameters were selected.

DATA SYNTHESIS:

The structural modification that distinguishes the azalide antibiotics from the macrolide antibiotics is responsible for the pharmacokinetic and pharmacodynamic behavior of azithromycin, resulting in the high and sustained tissue and intracellular concentrations seen with this agent. Drug delivery to the site of infection by phagocytes and fibroblasts is the hallmark of azithromycin's tissue-directed pharmacodynamics, allowing for convenient once-daily, 5-day regimens for most infections that respond to oral therapy and 7–10 days for more serious infections requiring initial intravenous therapy. Metabolism is via hepatic pathways other than cytochrome P450, thus minimizing the risk of drug interactions.

CONCLUSIONS:

Compared with other macrolide antibiotics, the unique pharmacokinetic and pharmacodynamic features of azithromycin offer the potential for improved efficacy and safety from drug interactions. These attributes, combined with its once-daily dosing schedule, make azithromycin suitable for the treatment of many types of bacterial infection.

Keywords

azithromycin pharmacokinetics azalide antibiotics macrolide antibiotics

Get full access to this article

View all access options for this article.

References

Haight

Finland

. Observations on mode of action of erythromycin. Proc Soc Exp Biol Med 1952;81:188–93.

Washington

II Wilson

. Erythromycin: A microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin Proc 1985;60: 189–203.

Prokesch

Hand

. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982;21:373–80.

Erythromycin. In: Kucers

Bennett

N McK

, eds. The use of antibiotics. Philadelphia: JB Lippincott, 1987:851.

Edelstein

Meyer

. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother 1980;18: 403–8.

Thacker

Bennett

Tsai

Fraser

McDade

Shepard

An outbreak in 1965 of severe respiratory illness caused by the Legionnaires' disease bacterium. J Infect Dis 1978;138:512–9.

Vildé

J-L

Dournon

Rajagopalan

. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother 1986;30:743–8.

Itoh

Suzuki

Nakaya

Inoue

Mitsuhashi

. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 1984;26: 863–9.

Catnach

Fairclough

. Erythromycin and the gut. Gut 1992;33: 397–401.

10.

Marlin

Thompson

Jenkins

Burgess

La Franier

. Study of serum levels, venous irritation, and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Hum Toxicol 1983;2:593–605.

11.

Peters

Friedel

McTavish

. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750–99.

12.

Luke

Foulds

Cohen

Levy

. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996;40:2577–81.

13.

Olsen

San Pedro

Gann

Gubbins

Halinski

Campbell

Jr.

Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996;40:2582–5.

14.

Gladue

Bright

Isaacson

Newborg

. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277–82.

15.

Donowitz

. Tissue-directed antibiotics and intracellular parasites: Complex interaction of phagocytes, pathogens, and drugs. Clin Infect Dis 1994;19:926–30.

16.

Foulds

Shepard

Johnson

. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 (suppl A):73–82.

17.

Package insert. Zithromax (azithromycin capsules; azithromycin tablets; azithromycin for oral suspension; and azithromycin for injection). New York: Pfizer Laboratories, 1997.

18.

Harris

Hilligoss

Colangelo

Eller

Okerholm

. Azithro-mycin and terfenadine: Lack of drug interaction. Clin Pharmacol Ther 1995;58:310–5.

19.

Ballow

Amsden

. Azithromycin: The first azalide antibiotic. Ann Pharmacother 1992;26:1253–61.

20.

Piscitelli

Danziger

Rodvold

. Clarithromycin and azithromycin: New macrolide antibiotics. Clin Pharm 1992;11:137–52.

21.

Hardy

Hensey

Beyer

Vojtko

McDonald

Fernandes

. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710–9.

22.

American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148: 1418–26.

23.

Principi

. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995;14:669–76.

24.

National Committee for Clinical Laboratory Standards. Table 2E, MIC interpretive standards (μg/mL) for Haemophilus spp. 1998:64–5.

25.

National Committee for Clinical Laboratory Standards. Table 2G, MIC interpretive standards (μg/mL) for Streptococcus pneumoniae. 1998:68–9.

26.

National Committee for Clinical Laboratory Standards. Table 2C, MIC interpretive standards (μg/mL) for Staphylococcus spp. 1998:56–9.

27.

Thompson

Washington

. Epidemiology of sexually transmitted Chlamydia trachomatis infections. Epidemiol Rev 1983;5:96–123.

28.

Cassell

Cole

. Mycoplasmas as agents of human disease. N Engl J Med 1981;304:80–9.

29.

McDade

Shepard

Fraser

Tsai

Redus

Dowdle

. Legionnaires' disease: Isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med 1977;297:1197–203.

30.

Wildfeuer

Laufen

Zimmermann

. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 1996;40:75–9.

31.

Lalak

Morris

. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370–4.

32.

Pruul

McDonald

. Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. Antimicrob Agents Chemother 1992;36:10–6.

33.

Pruul

McDonald

. Potentiation of azithromycin activity against Escherichia coli by human serum ultrafiltrate. J Antimicrob Chemother 1992;30:497–507.

34.

Gladue

Snider

. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34: 1056–60.

35.

Foulds

Chan

Johnson

Shepard

Johnson

. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991;10:853–6.

36.

Baldwin

Wise

Andrews

Ashby

Honeybourne

. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990;3:886–90.

37.

Gris

. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: Results of a randomized, double-blind comparative study. J Antimicrob Chemother 1996;37(suppl C):93–101.

38.

Vaudaux

Cherpillod

Dayer

. Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996;37(suppl C):45–51.

39.

Rodriguez

. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother 1996;37(suppl C):63–9.

40.

Montero

. A comparative study of the efficacy, safety, and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother 1996;37(suppl C):125–31.

41.

O'Doherty

. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):71–81.

42.

Zachariah

. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):103–13.

43.

Laurent

. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):115–24.

44.

Patel

Xuan

Tessier

Russomanno

Quintilianie

Nightingale

. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375–9.

45.

Carlier

Scorneaux

Tulkens

. Accumulation, subcellular distribution and activity of azithromycin (Az) compared to roxithromycin (Rx) and ciprofloxacin (Cp) in J774 macrophages (Mo) (abstract). 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991.

46.

Schentag

Ballow

. Tissue-directed pharmacokinetics. Am J Med 1991;91(suppl 3A):5S–11S.

47.

Frank

Sullivan

Carper

Mandell

. In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. Antimicrob Agents Chemother 1992;36:2584–8.

48.

Girard

Cimochowski

Faiella

. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother 1996;37(suppl C):9–19.

49.

Retsema

Bergeron

Girard

Milisen

. Preferential concentration of azithromycin in infected mouse thighs as compared to contralateral non-infected thighs (abstract). 91st General Meeting of the American Society for Microbiology, 1991.

50.

Tissi

von Hunolstein

Mosci

Campanelli

Bistoni

Orefici

. In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Antimicrob Agents Chemother 1995;39:1938–47.

51.

Girard

Regan

Milisen

Retsema

Swindell

. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. J Antimicrob Chemother 1996;37(suppl C):21–35.

52.

Amsden

. Macrolides versus azalides: A drug interaction update. Ann Pharmacother 1995;29:906–17.

53.

Amsden

. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin Therapeut 1996;18:56–72.

54.

Olkkola

Aranko

Luurila

Hiller

Saarnivaara

Himberg

J-J

A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298–305.

55.

Yeates

Laufen

Zimmermann

. Interaction between midazolam and clarithromycin: Comparison with azithromycin. Int J Clin Pharmacol Therapeut 1996;34:400–5.

56.

Piscitelli

Flexner

Minor

Polis

Masur

. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685–93.

57.

Honig

Wortham

Zamini

Conner

Cantilena

. Effect of erythromycin, clarithromycin, and azithromycin on the pharmacokinetics of terfenadine (abstract). Clin Pharmacol Ther 1993;53:161.

58.

Hopkins

. Clinical toleration and safety of azithromycin. Am J Med 1991;91(suppl 3A):40S–5S.